Another Large New Published Study Shows that Taking a Statin Drug Reduces the Risk of Dementia.

MAYWOOD, N.J. -- Nymox (NASDAQ:NYMX) Has Global Patent Rights for the Use of Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

Taking a statin drug reduces the risk of all types of dementia, including Alzheimer's disease, by 44% according to a large study

of 8,574 patients published in the current issue of Neurology (May, 2005; 64:1531-8). Statins are widely prescribed cholesterol-lowering drugs. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer's disease, the leading cause of dementia in the elderly.

In the study of persons aged 65 or more living in three cities in France, researchers compared the prevalence of dementia among those individuals who took a statin drug to lower their cholesterol against those who did not. Overall, the prevalence of dementia was 44% lower for those individuals taking a statin to lower cholesterol. Most of the dementia cases observed were Alzheimer's disease (65.1%).

Many significant scientific and clinical studies have showed the potential benefits of statin drugs in the prevention or treatment of Alzheimer's disease. Studies have shown up to 70% reduction in AD incidence in individuals who use statin drugs. In addition to recent studies presented at major medical conferences, published peer-reviewed studies include, for example, Archives of Neurology May, 2005; 62:753-7; International Journal of Geriatric Psychiatry 2004; 19:327-32; Neuroepidemiology 2004; 23:94-8; Neuron 2004; 41:7-10; Arch Neurol 2000; 57:1439-1443; Lancet 2000; 356:1627-1631; Arch Neurol 2002; 59:223-227; J Gerontol Biol Sci Med Sci 2002;57:M414-M418; and J Am Geriatr Soc 2002;50:1852-1856.

The potential for the use of statin drugs to treat or reduce the risk of Alzheimer's disease has also been featured extensively in the media such as New York Times (April 13, 2004), Fortune magazine (August 9, 2004), Newsweek magazine (Jan 19, 2004), Los Angeles Times (June 22, 2003), and The Wall Street Journal (April 17 and 18, 2002).

According to a recent study (Arch Neurol 2003; 60: 1119-1122), there are 4.5 million people with Alzheimer's disease in the United States alone; by 2050 this number is projected to increase almost three times to 13.2 million. Worldwide estimates of the current number of people with Alzheimer's disease range from 15 to 20 million. The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone is estimated at $100 billion. The human toll on patients, families and caregivers is incalculable.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox has developed AlzheimAlert(TM), a U.S. CLIA-certified test to aid in the diagnosis of Alzheimer's disease. The Company has successfully completed two U.S. Phase 1 and Phase 1-2 clinical trials for NX-1207, its drug for benign prostatic hyperplasia (BPH). The Company markets NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure. Nymox has a number of drugs in development for Alzheimer's disease, oncology, and infectious disease.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.